Opus Genetics (IRD) Other Accumulated Expenses (2019 - 2025)
Opus Genetics (IRD) posted quarterly Other Accumulated Expenses of $268000.0 for Q3 2025, up 325.4% year-over-year from $63000.0 in Q3 2024, and up 1.13% quarter-over-quarter from $265000.0 in Q2 2025.
Powered by 
Analysis
Opus Genetics (IRD) Other Accumulated Expenses (2019 - 2025) Analysis & Trends
Opus Genetics (IRD) has reported Other Accumulated Expenses for 7 consecutive years, with $268000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Other Accumulated Expenses rose 325.4% year-over-year to $268000.0; the TTM figure through Sep 2025 stood at $268000.0 (up 325.4% YoY), while the FY2024 annual figure was $606000.0, up 753.52% from the prior year.
- Other Accumulated Expenses improved to $268000.0 in Q3 2025 per IRD's latest filing, from $265000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $606000.0 in Q4 2024 and bottomed at $8000.0 in Q3 2021.
- Historically, Other Accumulated Expenses has averaged $129789.5 across 5 years, with a median of $74000.0 in 2022.
- Annual changes were most pronounced in 2022 — Other Accumulated Expenses surged 825.0% — and 2023, when it slumped 57.49%.
- Opus Genetics' Other Accumulated Expenses stood at $80000.0 in 2021, then surged by 108.75% to $167000.0 in 2022, then plunged by 57.49% to $71000.0 in 2023, then surged by 753.52% to $606000.0 in 2024, then plunged by 55.78% to $268000.0 in 2025.
- Business Quant data shows IRD's Other Accumulated Expenses at $268000.0 in Q3 2025, $265000.0 in Q2 2025, and $380000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 268,000.00 |
| Jun 30, 2025 | 265,000.00 |
| Mar 31, 2025 | 380,000.00 |
| Dec 31, 2024 | 606,000.00 |
| Sep 30, 2024 | 63,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Mar 31, 2024 | 95,000.00 |
| Dec 31, 2023 | 71,000.00 |
| Sep 30, 2023 | 49,000.00 |
| Jun 30, 2023 | 45,000.00 |
| Mar 31, 2023 | 43,000.00 |
| Dec 31, 2022 | 167,000.00 |
| Sep 30, 2022 | 74,000.00 |
| Jun 30, 2022 | 39,000.00 |
| Mar 31, 2022 | 75,000.00 |
| Dec 31, 2021 | 80,000.00 |
| Sep 30, 2021 | 8,000.00 |
| Jun 30, 2021 | 16,000.00 |
| Mar 31, 2021 | 26,000.00 |
| Dec 31, 2020 | 25,000.00 |